BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28038451)

  • 1. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
    Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
    Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
    Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
    Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression.
    Zhao JC; Fong KW; Jin HJ; Yang YA; Kim J; Yu J
    Oncogene; 2016 Aug; 35(33):4335-44. PubMed ID: 26751772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Hankey W; Chen Z; Wang Q
    Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.
    He B; Lanz RB; Fiskus W; Geng C; Yi P; Hartig SM; Rajapakshe K; Shou J; Wei L; Shah SS; Foley C; Chew SA; Eedunuri VK; Bedoya DJ; Feng Q; Minami T; Mitsiades CS; Frolov A; Weigel NL; Hilsenbeck SG; Rosen DG; Palzkill T; Ittmann MM; Song Y; Coarfa C; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18261-6. PubMed ID: 25489091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
    Yenki P; Bhasin S; Liu L; Nabavi N; Cheng CW; Tam KJ; Peacock JW; Adomat HH; Tombe T; Fazli L; Ivanova L; Dusek C; Khosravi S; Guns EST; Wang Y; Buttyan R; Gleave ME; Ong CJ
    Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37800655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Shen T; Dong B; Meng Y; Moore DD; Yang F
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells.
    Lee HJ; Hwang M; Chattopadhyay S; Choi HS; Lee K
    Biochem Biophys Res Commun; 2008 Mar; 367(2):481-6. PubMed ID: 18178153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
    Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
    Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2.
    Seo WY; Jeong BC; Yu EJ; Kim HJ; Kim SH; Lim JE; Kwon GY; Lee HM; Kim JH
    Nucleic Acids Res; 2013 Oct; 41(18):8526-36. PubMed ID: 23887938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
    Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
    Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.